Literature DB >> 33055571

Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States.

Jillian Pintye1, Yanling Huo2, Deborah Kacanek2, Kevin Zhang3, Karen Kuncze3, Hideaki Okochi3, Monica Gandhi3.   

Abstract

OBJECTIVE: We evaluated peripartum tenofovir (TFV) exposure via hair measures among women living with HIV in the United States.
DESIGN: Observational cohort study.
METHODS: Hair samples were collected at or shortly after childbirth among mothers enrolled in the Surveillance Monitoring for Antiretroviral Therapy Toxicities Study of the Pediatric HIV/AIDS Cohort Study between 6/2014 and 7/2016. Among mothers receiving TFV disoproxil fumarate (TDF)-based regimens during pregnancy, TFV hair concentrations were analyzed using liquid chromatography/tandem mass spectrometry. Weight-normalized TFV concentrations were log10 transformed. Multivariable linear regression assessed correlates of TFV concentrations.
RESULTS: Overall, 121 mothers on TDF-based antiretroviral therapy during pregnancy had hair specimens tested for TFV concentrations and were included in the analysis. Median age at delivery was 31 years [interquartile range (IQR) 26-36]; 71% self-identified as non-Hispanic black, and 10% had unsuppressed viral loads in late pregnancy (HIV RNA ≥ 400 copies/ml). Median time from birth to hair collection was 3 days (IQR 1-14) and median TFV hair concentration was 0.02 ng/mg (IQR 0.01-0.04). In multivariable models, an unsuppressed viral load in late pregnancy was associated with 80% lower adjusted mean peripartum TFV concentrations than pregnancies with viral suppression (95% confidence interval: -90% to -59%, P < 0.001). Use of TDF only in the first trimester and attaining high school graduation were also associated with lower TFV hair concentrations.
CONCLUSION: Unsuppressed viral load during late pregnancy was strongly associated with lower maternal TFV hair concentrations at birth, though viremia was rare. Efforts to improve maternal virological outcomes and eliminate vertical HIV transmission could incorporate drug exposure monitoring using hair or other metrics.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33055571      PMCID: PMC7775322          DOI: 10.1097/QAD.0000000000002730

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  37 in total

1.  Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.

Authors:  Katherine Tassiopoulos; Jennifer S Read; Susan Brogly; Kenneth Rich; Barry Lester; Stephen A Spector; Ram Yogev; George R Seage
Journal:  AIDS Behav       Date:  2010-12

2.  HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.

Authors:  L Myer; T K Phillips; J A McIntyre; N-Y Hsiao; G Petro; A Zerbe; J Ramjith; L-G Bekker; E J Abrams
Journal:  HIV Med       Date:  2016-06-28       Impact factor: 3.180

3.  Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.

Authors:  Monica Gandhi; Pamela M Murnane; Peter Bacchetti; Richard Elion; Michael A Kolber; Stephanie E Cohen; Howard Horng; Alexander Louie; Karen Kuncze; Catherine A Koss; Peter L Anderson; Susan Buchbinder; Albert Liu
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

4.  Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.

Authors:  Jeffrey Sa Stringer; Moses Sinkala; Courtney C Maclean; Jens Levy; Chipepo Kankasa; Alain Degroot; Elizabeth M Stringer; Edward P Acosta; Robert L Goldenberg; Sten H Vermund
Journal:  AIDS       Date:  2005-08-12       Impact factor: 4.177

5.  Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Authors:  Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

6.  Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.

Authors:  Elizabeth M Stringer; Didier K Ekouevi; David Coetzee; Pius M Tih; Tracy L Creek; Kathryn Stinson; Mark J Giganti; Thomas K Welty; Namwinga Chintu; Benjamin H Chi; Catherine M Wilfert; Nathan Shaffer; Francois Dabis; Jeffrey S A Stringer
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

Review 7.  Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring.

Authors:  Jose R Castillo-Mancilla; Jessica E Haberer
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

Review 8.  A meta-analysis of effectiveness of interventions to improve adherence in pregnant women receiving antiretroviral therapy in sub-Saharan Africa.

Authors:  Olumuyiwa Omonaiye; Pat Nicholson; Snezana Kusljic; Elizabeth Manias
Journal:  Int J Infect Dis       Date:  2018-07-09       Impact factor: 3.623

9.  Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.

Authors:  Maria Pyra; Peter L Anderson; Craig W Hendrix; Renee Heffron; Kenneth Mugwanya; Jessica E Haberer; Katherine K Thomas; Connie Celum; Deborah Donnell; Mark A Marzinke; Elizabeth A Bukusi; Nelly R Mugo; Stephen Asiimwe; Elly Katabira; Jared M Baeten
Journal:  AIDS       Date:  2018-08-24       Impact factor: 4.177

10.  Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Authors:  Catherine A Koss; Sybil G Hosek; Peter Bacchetti; Peter L Anderson; Albert Y Liu; Howard Horng; Leslie Z Benet; Karen Kuncze; Alexander Louie; Parya Saberi; Craig M Wilson; Monica Gandhi
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.